Amendments to the Claims:
This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:
1.- 36. (cancelled)

37. (currently amended) A method for treating a ~~mammal~~ human comprising administering subcutaneously a therapeutically effective amount of a stable reconstituted formulation to the ~~mammal~~ human in order to treat an IgE-mediated allergic disease in the ~~mammal~~ human, wherein the reconstituted formulation comprises an antibody which binds IgE in an amount ~~of~~ in the range from 80 ~~50~~ mg/mL to about 400mg/mL and has been prepared by reconstituting a lyophilized mixture of the antibody and a lyoprotectant in a diluent, wherein the antibody concentration in the reconstituted formulation is about 2-40 times greater than the antibody concentration in the mixture before lyophilization.

38.-43. (cancelled).

44. (currently amended) The method of claim ~~39~~ 37 wherein about 1-15 mg/kg of the antibody is administered to the human.

45. (currently amended) A method for treating a ~~mammal~~ human comprising administering subcutaneously a therapeutically effective amount of a formulation to the ~~mammal~~ human in order to treat an IgE-mediated allergic disease in the ~~mammal~~ human, wherein the formulation comprises an antibody which binds IgE in an amount ~~of~~ in the range from 80 ~~50~~ mg/mL to about 400mg/mL.

46. (currently amended) The method of claim 45 wherein the formulation comprises the IgE antibody in an amount ~~of~~ in the range from 80 mg/mL to about 300mg/mL.

47.-48 (Cancelled)

49. (previously presented) A method for treating a human comprising administering subcutaneously a therapeutically effective amount of a formulation to the human in order to treat an IgE-mediated allergic disease in

the human, wherein the formulation comprises an antibody which binds IgE in an amount in the range from 80 mg/mL to about 300mg/mL.